8-K Announcements
6Material company update
Apr 3, 2025·SEC
Material company update
Mar 21, 2025·SEC
Material company update
Feb 6, 2025·SEC
Virpax Pharmaceuticals, Inc.(VRPX)Earnings, Financials & Key Ratios
VRPX•NASDAQ
Price updated May 30, 2026
AboutVirpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical nonsteroidal anti-inflammatory drug treatment for chronic osteoarthritis of the knee; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise PES200, which enables the delivery of a metabolically labile peptide drug into the brain; AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and VRP324, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.Show more
- Revenue$0
- EBITDA-$12M+21.2%
- Net Income-$12M+20.6%
- EPS (Diluted)-70.91-446.7%
- ROE-2364.82%-1341.2%
- Interest Coverage-115.31
VRPX Key Insights
Virpax Pharmaceuticals, Inc. (VRPX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓High quality earnings: Operating CF exceeds net income
✗Weaknesses
- ✗Profits declining 28.6% over 5 years
- ✗Weak Piotroski F-Score: 0/9
- ✗Weak momentum: RS Rating 0 (bottom 0%)
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when VRPX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
VRPX Price & Volume
Virpax Pharmaceuticals, Inc. (VRPX) stock price & volume — 10-year historical chart
Loading chart...
VRPX Growth Metrics
Virpax Pharmaceuticals, Inc. (VRPX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM19.87%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM55.44%
Return on Capital
10 Years-671.94%
5 Years-671.94%
3 Years-872.54%
Last Year-2367.31%
VRPX Peer Comparison
Virpax Pharmaceuticals, Inc. (VRPX) competitors in Drug Delivery Technology Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NKTR | 1.27B | 64.88 | -6.67 | -43.89% | -284.18% | -87% | 1.66 | |
 PCRX | 913.36M | 23.22 | 145.13 | 3.63% | 1.27% | 1.31% | 0.66 | |
 PRAX | 10.11B | 349.97 | -25.96 | -100% | -43.02% | 0.00 | ||
 ABBV | 384.85B | 217.58 | 91.81 | 8.57% | 6.91% | 62.15% | ||
 PFE | 148.86B | 26.17 | 19.24 | -1.65% | 11.83% | 8.34% | 0.78 | |
 MRK | 293.22B | 118.72 | 16.31 | 1.18% | 28.12% | 36.14% | 0.96 | |
 IQV | 30.92B | 182.21 | 23.24 | 5.87% | 8.33% | 22.11% | 2.44 | |
 CRL | 8.7B | 180.71 | -62.10 | -0.85% | -4.59% | -5.66% | 0.95 |
Compare VRPX vs Peers
Virpax Pharmaceuticals, Inc. (VRPX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
VRPX Income Statement
Virpax Pharmaceuticals, Inc. (VRPX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 |
|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
COGS % of Revenue | - | - | - | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
Gross Margin % | - | - | - | - | - | - | - |
Gross Profit Growth % | - | - | - | - | - | - | - |
Operating Expenses | 2.63M | 3.18M | 4.2M | 12.03M | 21.85M | 15.69M | 12.08M |
OpEx % of Revenue | - | - | - | - | - | - | - |
Selling, General & Admin | 1.48M | 2.56M | 2.9M | 7.19M | 11.08M | 7.82M | 6.26M |
SG&A % of Revenue | - | - | - | - | - | - | - |
Research & Development | 1.14M | 622.74K | 1.29M | 4.84M | 10.76M | 5.12M | 5.82M |
R&D % of Revenue | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 4K | 62.26K | 194.41K | 2.75M | 0 |
Operating Income | -2.63M▲ 0% | -3.18M▼ 21.2% | -4.2M▼ 31.9% | -12.03M▼ 186.6% | -21.85M▼ 81.7% | -15.69M▲ 28.2% | -12.08M▲ 23.0% |
Operating Margin % | - | - | - | - | - | - | - |
Operating Income Growth % | - | -21.17% | -31.86% | -186.61% | -81.66% | 28.18% | 23.01% |
EBITDA | 0 | 0 | 0 | 0 | -3.5M | -15.19M | -11.96M |
EBITDA Margin % | - | - | - | - | - | - | - |
EBITDA Growth % | - | - | - | - | - | -333.99% | 21.24% |
D&A (Non-Cash Add-back) | 2.63M | 3.18M | 4.2M | 12.03M | 18.35M | 500.28K | 0 |
EBIT | -2.63M | -3.18M | -4.19M | -11.96M | -21.65M | -15.19M | -11.96M |
Net Interest Income | 0 | -124.52K | -147.79K | -92.73K | 0 | 0 | -103.75K |
Interest Income | 0 | 125 | 148 | 0 | 0 | 0 | 0 |
Interest Expense | 14.98K | 124.64K | 147.93K | 92.82K | 0 | 0 | 103.75K |
Other Income/Expense | -14.98K | -124.64K | -143.93K | -30.56K | 194.41K | 500.28K | 12.71K |
Pretax Income | -2.64M▲ 0% | -3.31M▼ 25.2% | -4.34M▼ 31.2% | -12.06M▼ 177.8% | -21.65M▼ 79.6% | -15.19M▲ 29.8% | -12.07M▲ 20.6% |
Pretax Margin % | - | - | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -2.64M▲ 0% | -3.43M▼ 29.9% | -4.49M▼ 30.8% | -12.15M▼ 170.7% | -21.46M▼ 76.6% | -15.19M▲ 29.2% | -12.07M▲ 20.6% |
Net Margin % | - | - | - | - | - | - | - |
Net Income Growth % | - | -29.92% | -30.79% | -170.72% | -76.61% | 29.21% | 20.56% |
Net Income (Continuing) | -2.64M | -3.31M | -4.34M | -12.06M | -21.65M | -15.19M | -12.07M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.53▲ 0% | -6.58▼ 1141.5% | -9.07▼ 37.8% | -10.37▼ 14.3% | -18.32▼ 76.7% | -12.97▲ 29.2% | -70.91▼ 446.7% |
EPS Growth % | - | -1141.51% | -37.84% | -14.33% | -76.66% | 29.2% | -446.72% |
EPS (Basic) | -0.53 | -6.58 | -9.07 | -10.37 | -18.32 | -12.97 | -70.91 |
Diluted Shares Outstanding | 4.95M | 521.51K | 494.51K | 1.17M | 1.17M | 1.17M | 4.25M |
Basic Shares Outstanding | 4.95M | 521.51K | 494.51K | 1.17M | 1.17M | 1.17M | 4.25M |
Dividend Payout Ratio | - | - | - | - | - | - | - |
VRPX Balance Sheet
Virpax Pharmaceuticals, Inc. (VRPX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 |
|---|---|---|---|---|---|---|---|
Total Current Assets | 61.5K | 46.72K | 73.07K | 39.57M | 19.67M | 9.63M | 1.56M |
Cash & Short-Term Investments | 48.37K | 41.54K | 54.8K | 36.84M | 19M | 9.14M | 1.51M |
Cash Only | 48.37K | 41.54K | 54.8K | 36.84M | 19M | 9.14M | 1.51M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 1.39K | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - |
Inventory | 0 | 3.33K | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - |
Other Current Assets | 10.5K | 467 | 535 | 2.57M | 496.27K | 283.37K | 37.91K |
Total Non-Current Assets | 0 | 0 | 392.34K | 0 | 0 | 0 | 0 |
Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Fixed Asset Turnover | - | - | - | - | - | - | - |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 392.34K | 0 | 0 | 0 | 0 |
Total Assets | 61.5K▲ 0% | 46.72K▼ 24.0% | 465.41K▲ 896.2% | 39.57M▲ 8402.8% | 19.67M▼ 50.3% | 9.63M▼ 51.1% | 1.56M▼ 83.8% |
Asset Turnover | - | - | - | - | - | - | - |
Asset Growth % | - | -24.03% | 896.18% | 8402.78% | -50.28% | -51.06% | -83.84% |
Total Current Liabilities | 1.25M | 2.78M | 3.66M | 2.09M | 3.09M | 7.69M | 2.47M |
Accounts Payable | 6.55K | 3.5K | 22.11K | 19.84K | 37.64K | 18.46K | 0 |
Days Payables Outstanding | - | - | - | - | - | - | - |
Short-Term Debt | 500K | 1.26M | 543.99K | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | -6.55K | -3 | -1.05M | 0 | 0 | 0 | 0 |
Other Current Liabilities | 7.46K | 819.61K | 1.03M | 0 | 2M | 6M | 0 |
Current Ratio | 0.05x | 0.02x | 0.02x | 18.96x | 6.36x | 1.25x | 0.63x |
Quick Ratio | 0.05x | 0.02x | 0.02x | 18.96x | 6.36x | 1.25x | 0.63x |
Cash Conversion Cycle | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 500K | 0 | 1.02M | 0 | 1.09K | 0 | 0 |
Long-Term Debt | 0 | 0 | 1.02M | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 1.25M | 2.78M | 4.68M | 2.09M | 3.09M | 7.69M | 2.47M |
Total Debt | 500K | 1.26M | 1.57M | 0 | 0 | 0 | 0 |
Net Debt | 451.63K | 1.22M | 1.51M | -36.84M | -19M | -9.14M | -1.51M |
Debt / Equity | - | - | - | - | - | - | - |
Debt / EBITDA | - | - | - | - | - | - | - |
Net Debt / EBITDA | - | - | - | - | - | - | - |
Interest Coverage | -175.34x | -25.53x | -28.34x | -128.88x | - | - | -115.31x |
Total Equity | -1.19M▲ 0% | -2.73M▼ 129.1% | -4.22M▼ 54.3% | 37.48M▲ 989.1% | 16.58M▼ 55.8% | 1.93M▼ 88.3% | -913.76K▼ 147.2% |
Equity Growth % | - | -129.08% | -54.31% | 989.09% | -55.77% | -88.33% | -147.24% |
Book Value per Share | -0.24 | -5.24 | -8.53 | 32.00 | 14.16 | 1.65 | -0.21 |
Total Shareholders' Equity | -1.19M | -2.73M | -4.22M | 37.48M | 16.58M | 1.93M | -913.76K |
Common Stock | 29 | 30 | 31 | 117 | 117 | 12 | 149 |
Retained Earnings | -3M | -6.31M | -10.65M | -22.7M | -44.35M | -59.54M | -71.61M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
VRPX Cash Flow Statement
Virpax Pharmaceuticals, Inc. (VRPX) cash flow — operating, investing & free cash flow history
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 |
|---|---|---|---|---|---|---|---|
Cash from Operations | -1.8M | -1.13M | -1.38M | -14.54M | -17.85M | -9.85M | -16.71B |
Operating CF Margin % | - | - | - | - | - | - | - |
Operating CF Growth % | - | 37.11% | -22.36% | -950.11% | -22.72% | 44.79% | -169509.16% |
Net Income | -2.64M | -3.31M | -4.34M | -12.06M | -21.65M | -15.19M | -12.07M |
Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Stock-Based Compensation | 384.95K | 678.15K | 1.47M | 974.23K | 745.03K | 544.77K | 134.7M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 14.98K | 564.64K | 153.22K | -61.82K | 745.03K | 599.43K | -16.83B |
Working Capital Changes | 441.37K | 931.89K | 1.33M | -3.4M | 3.06M | 4.19M | -4.78M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 454.5K | 923.94K | 1.34M | -686.78K | -993.1K | 0 | 0 |
Cash from Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CapEx % of Revenue | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 1.67M | 1.13M | 1.4M | 51.33M | 0 | 0 | 9.08B |
Debt Issued (Net) | 554.77K | 500K | 72.1K | -1.5M | 0 | 0 | 0 |
Equity Issued (Net) | 1.12M | 0 | 1.38M | 58.02M | 0 | 0 | 6.32M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 625K | -50.88K | -5.19M | 0 | 0 | 9.08B |
Net Change in Cash | -124.87K▲ 0% | -6.83K▲ 94.5% | 13.26K▲ 294.0% | 36.79M▲ 277329.8% | -17.85M▼ 148.5% | -9.85M▲ 44.8% | -7.63B▼ 77316.6% |
Free Cash Flow | -1.8M▲ 0% | -1.13M▲ 37.1% | -1.38M▼ 22.4% | -14.54M▼ 950.1% | -17.85M▼ 22.7% | -9.85M▲ 44.8% | -16.71B▼ 169509.2% |
FCF Margin % | - | - | - | - | - | - | - |
FCF Growth % | - | 37.11% | -22.36% | -950.11% | -22.72% | 44.79% | -169509.16% |
FCF per Share | -0.36 | -2.17 | -2.80 | -12.41 | -15.24 | -8.41 | -3928.38 |
FCF Conversion (FCF/Net Income) | 0.68x | 0.33x | 0.31x | 1.20x | 0.83x | 0.65x | 1384.98x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
VRPX Key Ratios
Virpax Pharmaceuticals, Inc. (VRPX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | - | -73.04% | -79.37% | -164.09% | -2364.82% |
| Interest Coverage | -175.34x | -25.53x | -28.34x | -128.88x | - | - | -115.31x |
| FCF Conversion | 0.68x | 0.33x | 0.31x | 1.20x | 0.83x | 0.65x | 1384.98x |
Related:VRPX Dividend History·VRPX Revenue History·VRPX Price History·VRPX P/E History·VRPX Financial Ratios·VRPX Institutional Holders
VRPX SEC Filings & Documents
Virpax Pharmaceuticals, Inc. (VRPX) SEC filings — annual & quarterly reports (10-K, 10-Q)
VRPX Frequently Asked Questions
Virpax Pharmaceuticals, Inc. (VRPX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Virpax Pharmaceuticals, Inc. (VRPX) grew revenue by 0.0% over the past year. Growth has been modest.
Virpax Pharmaceuticals, Inc. (VRPX) reported a net loss of $12.1M for fiscal year 2024.
Dividend & Returns
Virpax Pharmaceuticals, Inc. (VRPX) has a return on equity (ROE) of -2364.8%. Negative ROE indicates the company is unprofitable.
Virpax Pharmaceuticals, Inc. (VRPX) had negative free cash flow of $16.7M in fiscal year 2024, likely due to heavy capital investments.